New UK specialist biotech company Mereo BioPharma is on the look-out for a handful of further promising products to add to the three clinical-stage products it has just acquired from Novartis, according to company CEO Denise Scots-Knight.
The formation of Mereo BioPharma is being funded with $119m from UK institutional investors in a series A round, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?